Highest development stage: Phase 1 Clinical Trial (NCT03563599)

Development status: Active (as of 2023)

Mechanism of Action/Target pathogen: Active against <i>Mycobacterium tuberculosis</i>; inhibits mycobacterial cytochrome bc1 complex

Additional information: Synthetic compound; shows a synergistic effect with PBTZ169 (Phase 2 anti-tuberculosis drug derived from BTZ-043)